This is an incredibly challenging time, but at MannKind, it has also deepened our passion for helping people with diabetes. Please see below for a compilation of all applicable resources.
Given the current circumstances, many may be unable or unwilling to visit the offices of healthcare providers during this time. As always, AfrezzaAssist offers all of its services virtually.
You can also explore our library of self-guided training videos and resources.
Whether you’ve lost or changed insurance, are worried about continuing to be able to get your Afrezza®, or are experiencing a unique challenge – AfrezzaAssist is here for you. MannKind offers several support options which may be available to you, depending on your insurance and circumstance, to help you navigate the current coronavirus situation.
Call us at 1-844-323-7399 to discuss with a Patient Support Guide what options may be available to you.
Please note: If AfrezzaAssist is unable to answer at the time of your call, please leave us a voicemail and we will follow up with you within 1 business day. We appreciate your understanding while we help all our customers. Please visit https://afrezza.com/faqs to find answers to product-related questions.
With the spread of the coronavirus, many individuals are concerned about access to their medication supply. At this time, MannKind anticipates a stable supply of Afrezza® that will not be affected by the coronavirus pandemic.
We will continue to closely monitor our supply chain for potential impact to the supply of Afrezza®. MannKind sources critical raw materials from suppliers in the United States and Europe and we remain in close communication with key suppliers to assure a reliable supply of insulin. Our US manufacturing facility is fully operational and we are taking a number of steps to prevent any impact to our supplies.
Afrezza® is still readily available in U.S. pharmacies (including mail-order), and if needed, pharmacies can order additional supplies from wholesalers with expected delivery within 1-2 days. As the global situation evolves, we will continue to take the necessary steps to safeguard the reliable supply of Afrezza®.
Together with the JDRF & Beyond Type 1 Alliance, MannKind is sharing guidance on recommendations for people living with diabetes to reduce risk of complications caused by the coronavirus.
Check out www.coronavirusdiabetes.org to see the list of recommendations, downloadable graphics, videos and links to additional resources – many available in both English and Spanish!
Afrezza® can cause serious side effects, including: Sudden lung problems (bronchospasms). Do not use Afrezza® if you have long-term (chronic) lung problems such as asthma or chronic obstructive pulmonary disease (COPD). Before starting Afrezza®, your healthcare provider will give you a breathing test to check how your lungs are working.
What is the most important information I should know about Afrezza®?
Afrezza® can cause serious side effects, including:
Sudden lung problems (bronchospasms). Do not use Afrezza® if you have long-term (chronic) lung problems such as asthma or chronic obstructive pulmonary disease (COPD). Before starting Afrezza®, your healthcare provider will give you a breathing test to check how your lungs are working.
Do not use Afrezza® if you:
Before using Afrezza®, tell your healthcare provider about all your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins or herbal supplements.
Before you start using Afrezza®, talk to your healthcare provider about low blood sugar and how to manage it.
While using Afrezza® do not:
Afrezza® may cause serious side effects that can lead to death, including:
See “What is the most important information I should know about Afrezza®?” at the top of this page.
Treatment with TZDs and Afrezza® may need to be changed or stopped by your healthcare provider if you have new or worse heart failure.
Get emergency medical help if you have:
• Trouble breathing, shortness of breath, fast heartbeat, swelling of your face, tongue, or throat, sweating, extreme drowsiness, dizziness, confusion.
The most common side effects of Afrezza® include:
These are not all the possible side effects of Afrezza®. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 (1-800-332-1088).
Active ingredient: human insulin
Inactive ingredients: fumaryl diketopiperazine, polysorbate 80
General information about the safe and effective use of Afrezza®.
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use Afrezza® for a condition for which it was not prescribed. Do not give Afrezza® to other people, even if they have the same symptoms that you have. It may harm them.
This Medication Guide summarizes the most important information about Afrezza®. If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about Afrezza® that is written for health professionals.
AFREZZA®, MANNKIND, and the Afrezza® and MannKind logos are registered marks, all owned by MannKind Corporation. © MannKind Corporation 2020.
This site is intended for use by U.S. residents only